Dr. Arash Rashidi, MD

Dr. Rashidi practices at Advanced Vascular Access, LLC in Cleveland, Ohio.

Dr. Rashidi's NPI, 1790774289, was assigned on October 18, 2005. Dr. Rashidi holds Ohio license 35-084711.

Dr. Rashidi's primary practice is Advanced Vascular Access, LLC, at 20455 Lorain Rd, Cleveland, OH 44126 in Cuyahoga County. The practice phone is (440) 799-4811.

Dr. Rashidi's primary practice is Advanced Vascular Access, LLC in Cleveland, Ohio. Dr. Rashidi is also affiliated with University Hospitals Cleveland Medical Center. The medical group on file is University Hospitals Medical Practices. Dmand AI also links Dr. Rashidi to 4 more hospitals, 3 dialysis centers, 3 medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rashidi practices, 10 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Rashidi's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Rashidi is licensed in Ohio.

CMS data shows 1,310 Medicare services from Dr. Rashidi across 9 procedure codes in 2024, for 594 Medicare patients. Medicare paid $105,741 for them.

CMS counts 594 Medicare patients who saw Dr. Rashidi in 2024. The largest group is 65 to 74, with 246 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 11% are also on Medicaid. Their average risk score is 2.35, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rashidi's median patient age at 71, with 47% women.

In 2024, Dr. Rashidi wrote 5,949 Medicare Part D claims for 895 patients. 87% of them were for generic drugs. CMS names the drug for 5,891 of them, across 44 drugs with 11 or more claims each, at $836,950 in total drug cost. In 2023, CMS named 4,918 claims across 36 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Rashidi for performance year 2024, reported through an alternative payment model (APM). Dr. Rashidi accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 25 papers to Dr. Rashidi, published from 2012 to 2025. 2022 was the busiest year, with 4. The most frequent topics are Acute Kidney Injury, Immune Checkpoint Inhibitors and COVID-19. Dr. Rashidi has published most often in Am J Kidney Dis. Dr. Rashidi's most frequent co-authors are Ala Abudayyeh, MD, Sandra M. Herrmann, MD and Amanda D. Renaghan, MD.

CMS Open Payments shows 201 general payments to Dr. Rashidi from 27 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 83% of the total. Otsuka America Pharmaceutical, Inc. paid the most, $60,732.